In Britain passed the first stage of the test, "Oxford vaccine" from COVID-19

The coronavirus vaccine, developed by scientists at Oxford University, has successfully passed the first phase of the test, announced on Monday the developers of the vaccine, published the results of testing in the British medical journal The Lancet.

In testing the vaccine, dubbed nCoV ChAdOx1-19, in the period from 23 April to 21 may was attended by 1077 people. Vaccination has led to the development of the subjects of the antibodies to COVID-19, said the authors.

"The vaccine ChAdOx1 nCoV-19 causes an increase in antibodies to coronavirus at day 28," - said in the article.

"This is very positive news. A huge thanks to our brilliant, the world's leading scientists and researchers at @UniofOxford," wrote Prime Minister Boris Johnson on Twitter, adding that is not yet and will require further testing.

Vaccine COVID-19 is developed by Oxford University in conjunction with pharmaceutical company AstraZeneca.

Earlier in July, the Russian pharmaceutical company "R-Pharm", said that according to the agreement with AstraZeneca to produce in Russia the Oxford vaccine from COVID-19, including for export in 30-50 countries, including countries in the Middle East, Southeast Asia, Europe and the CIS.

Relevant data on the situation of COVID-19 in Russia and the world presented on the portal stopmanager.of the Russian Federation.